• Explore /
  • Poster
  • / Mobocertinib (TAK-788) in <em>EGFR</em> exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

Abstract Video & Slides Poster

Authors

Suresh Ramalingam

Suresh S. Ramalingam

Emory University, Atlanta, GA

Suresh S. Ramalingam , Caicun Zhou , Tae Min Kim , Sang-We Kim , James Chih-Hsin Yang , Gregory J. Riely , Tarek Mekhail , Danny Nguyen , Maria Rosario García Campelo , Enriqueta Felip , Sylvie Vincent , Shu Jin , Veronica Bunn , Jianchang Lin , Huamao Mark Lin , Minal Mehta , Pasi A. Janne

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02716116

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9014)

DOI

10.1200/JCO.2021.39.15_suppl.9014

Abstract #

9014

Abstract Disclosures

Similar Posters

First Author: Joel W. Neal

First Author: Jonathan N. Priantti

First Author: Alexander I. Spira

First Author: Baolan Li